{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:23:53Z","timestamp":1788391433214,"version":"build-2803163510"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.eclinm.2024.102425","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T04:47:01Z","timestamp":1705985221000},"page":"102425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Safety and efficacy of sequential treatments for postmenopausal osteoporosis: a network meta-analysis of randomised controlled trials"],"prefix":"10.1016","volume":"68","author":[{"given":"Yu-Xin","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yao","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Xuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junaid","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Min","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Hong","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9131-4141","authenticated-orcid":false,"given":"Hou-De","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.eclinm.2024.102425_bib1","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","article-title":"Treatment of postmenopausal osteoporosis","volume":"338","author":"Eastell","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102425_bib2","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/jbmr.2269","article-title":"The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine","volume":"29","author":"Wright","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"issue":"24","key":"10.1016\/j.eclinm.2024.102425_bib3","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/jama.2018.7498","article-title":"Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement","volume":"319","author":"Curry","year":"2018","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.eclinm.2024.102425_bib4","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.2009.1462","article-title":"Incidence and mortality of hip fractures in the United States","volume":"302","author":"Brauer","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2024.102425_bib5","first-page":"154","article-title":"Economic burden of osteoporosis in the world: a systematic review","volume":"34","author":"Rashki Kemmak","year":"2020","journal-title":"Med J Islam Repub Iran"},{"key":"10.1016\/j.eclinm.2024.102425_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115516","article-title":"Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches","volume":"139","author":"Langdahl","year":"2020","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102425_bib7","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/AOG.0000000000004730","article-title":"Management of postmenopausal osteoporosis: ACOG Clinical Practice Guideline No. 2","volume":"139","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102425_bib8","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"10329","key":"10.1016\/j.eclinm.2024.102425_bib9","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","article-title":"Drug therapy for osteoporosis in older adults","volume":"399","author":"Reid","year":"2022","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.eclinm.2024.102425_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102425_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int"},{"issue":"49","key":"10.1016\/j.eclinm.2024.102425_bib12","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005496","article-title":"The effect of sequential therapy for postmenopausal women with osteoporosis: a PRISMA-compliant meta-analysis of randomized controlled trials","volume":"95","author":"Lou","year":"2016","journal-title":"Medicine"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102425_bib13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2024.102425_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102425_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/M19-0533","article-title":"Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review","volume":"171","author":"Fink","year":"2019","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102425_bib16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13018-018-0865-3","article-title":"Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis","volume":"13","author":"Wu","year":"2018","journal-title":"J\u00a0Orthop Surg Res"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102425_bib17","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society\u2217Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eclinm.2024.102425_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"7454","key":"10.1016\/j.eclinm.2024.102425_bib19","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102425_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102425_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"10347","key":"10.1016\/j.eclinm.2024.102425_bib22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0140-6736(22)00878-9","article-title":"Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis","volume":"400","author":"De Crescenzo","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102425_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.eclinm.2024.102425_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2288-13-35","article-title":"A\u00a0graphical tool for locating inconsistency in network meta-analyses","volume":"13","author":"Krahn","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"7\u20138","key":"10.1016\/j.eclinm.2024.102425_bib25","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2024.102425_bib26","article-title":"Network meta-analysis: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102425_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056044","article-title":"Estimation of sleep problems among pregnant women during COVID-19 pandemic: a systematic review and meta-analysis","volume":"12","author":"Alimoradi","year":"2022","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102425_bib28","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102425_bib29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00198-007-0485-y","article-title":"Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis","volume":"19","author":"Adami","year":"2008","journal-title":"Osteoporos Int"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102425_bib30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archinte.163.7.789","article-title":"Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial","volume":"163","author":"Ascott-Evans","year":"2003","journal-title":"Arch Intern Med"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102425_bib31","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102425_bib32","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1210\/jc.2013-2020","article-title":"Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial","volume":"98","author":"Bonnick","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"16","key":"10.1016\/j.eclinm.2024.102425_bib33","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102425_bib34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00198-007-0475-0","article-title":"Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy","volume":"19","author":"Cosman","year":"2008","journal-title":"Osteoporos Int"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102425_bib35","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102425_bib36","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1359\/jbmr.081215","article-title":"Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)","volume":"24","author":"Eastell","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102425_bib37","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s00198-006-0157-3","article-title":"Teriparatide's effects on quantitative ultrasound parameters and bone density in women with established osteoporosis","volume":"17","author":"Gonnelli","year":"2006","journal-title":"Osteoporos Int"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102425_bib38","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00198-021-05996-2","article-title":"A\u00a0randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05","volume":"32","author":"Hagino","year":"2021","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102425_bib39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2302\/kjm.52.113","article-title":"Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis","volume":"52","author":"Iwamoto","year":"2003","journal-title":"Keio J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102425_bib40","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"issue":"9999","key":"10.1016\/j.eclinm.2024.102425_bib41","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102425_bib42","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102425_bib43","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1210\/jc.2004-2212","article-title":"The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis","volume":"91","author":"Michalsk\u00e1","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102425_bib44","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102425_bib45","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/jbmr.1716","article-title":"Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density","volume":"28","author":"Muschitz","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102425_bib46","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"15","key":"10.1016\/j.eclinm.2024.102425_bib47","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102425_bib48","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1210\/clinem\/dgz162","article-title":"Effect of abaloparatide vs alendronate on fracture risk reduction in postmenopausal women with osteoporosis","volume":"105","author":"Leder","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102425_bib49","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102425_bib50","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s00198-020-05502-0","article-title":"A\u00a0single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab","volume":"31","author":"McClung","year":"2020","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102425_bib51","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102425_bib52","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00198-012-2052-4","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial","volume":"24","author":"McClung","year":"2013","journal-title":"Osteoporos Int"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102425_bib53","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102425_bib54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00198-022-06570-0","article-title":"Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05","volume":"34","author":"Mori","year":"2023","journal-title":"Osteoporos Int"},{"issue":"9886","key":"10.1016\/j.eclinm.2024.102425_bib55","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the data study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102425_bib56","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s00198-022-06444-5","article-title":"Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Malaysia","volume":"33","author":"Choo","year":"2022","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eclinm.2024.102425_bib57","article-title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials","volume":"381","author":"H\u00e4ndel","year":"2023","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102425_bib58","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00198-020-05802-5","article-title":"Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy","volume":"32","author":"Hiligsmann","year":"2021","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102425_bib59","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.21037\/apm-20-1294","article-title":"Comparative efficacy between monoclonal antibodies and conventional drugs in postmenopausal women with osteoporosis: a network meta-analysis","volume":"10","author":"Jiang","year":"2021","journal-title":"Ann Palliat Med"},{"issue":"14","key":"10.1016\/j.eclinm.2024.102425_bib60","first-page":"3043","article-title":"Efficacy and safety of postmenopausal osteoporosis treatments: a systematic review and network meta-analysis of randomized controlled trials","volume":"10","author":"Lin","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.eclinm.2024.102425_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.839885","article-title":"Comparative efficacy of Xianling Gubao Capsules in improving bone mineral density in postmenopausal osteoporosis: a network meta-analysis","volume":"13","author":"Luo","year":"2022","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102425_bib62","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/s13018-021-02678-x","article-title":"Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis","volume":"16","author":"Migliorini","year":"2021","journal-title":"J\u00a0Orthop Surg Res"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102425_bib63","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00223-023-01078-z","article-title":"The clinical effectiveness of denosumab (Prolia\u00ae) for the treatment of osteoporosis in postmenopausal women, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis","volume":"112","author":"Moshi","year":"2023","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eclinm.2024.102425_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116610","article-title":"Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: a systematic review and Bayesian network meta-analysis","volume":"167","author":"Seeto","year":"2023","journal-title":"Bone"},{"issue":"17","key":"10.1016\/j.eclinm.2024.102425_bib65","first-page":"8253","article-title":"Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials","volume":"27","author":"Wang","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102425_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11880","article-title":"Efficacy and safety of pharmacologic therapies for prevention of osteoporotic vertebral fractures in postmenopausal women","volume":"9","author":"Wei","year":"2023","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102425_bib67","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102425_bib68","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1210\/js.2018-00118","article-title":"Osteoanabolic agents for osteoporosis","volume":"2","author":"Haas","year":"2018","journal-title":"J\u00a0Endocr Soc"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102425_bib69","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2008-0353","article-title":"Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate","volume":"93","author":"Miller","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102425_bib70","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102425_bib71","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/jbm4.10041","article-title":"Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy","volume":"2","author":"Leder","year":"2018","journal-title":"JBMR Plus"},{"key":"10.1016\/j.eclinm.2024.102425_bib72","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/164_2020_354","article-title":"Reduced bone modeling and unbalanced bone remodeling: targets for antiresorptive and anabolic therapy","volume":"262","author":"Ramchand","year":"2020","journal-title":"Handb Exp Pharmacol"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102425_bib73","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/jbmr.3198","article-title":"Effects of denosumab and teriparatide transitions on bone microarchitecture and estimated strength: the DATA-Switch HR-pQCT study","volume":"32","author":"Tsai","year":"2017","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102425_bib74","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00198-022-06626-1","article-title":"A\u00a0systematic review of cost-effectiveness analyses of sequential treatment for osteoporosis","volume":"34","author":"Yu","year":"2023","journal-title":"Osteoporos Int"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702400004X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702400004X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T23:10:55Z","timestamp":1728601855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258953702400004X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":74,"alternative-id":["S258953702400004X"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102425","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of sequential treatments for postmenopausal osteoporosis: a network meta-analysis of randomised controlled trials","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102425"}}